Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial

Core Viewpoint - Pfizer and Valneva have reported positive topline results from their phase three study of a Lyme disease vaccine candidate [1] Group 1 - The phase three study indicates promising efficacy for the Lyme disease vaccine [1] - The collaboration between Pfizer and Valneva highlights the growing focus on vaccine development in the pharmaceutical industry [1]